Article Information
- Received April 13, 2011
- Revision received November 30, 2012
- Accepted December 22, 2012
- First published February 27, 2013.
- Version of record published February 27, 2013.
Author Information
Author contributions
Author contributions: K.H.C., J.H., C.G.R., C.H., and M.D.E. designed research; K.H.C., J.H., C.G.R., and C.H. performed research; K.H.C., J.H., C.G.R., and C.H. contributed unpublished reagents/analytic tools; K.H.C., J.H., C.G.R., and C.H. analyzed data; K.H.C. and M.D.E. wrote the paper.
Disclosures
- Received April 13, 2011.
- Revision received November 30, 2012.
- Accepted December 22, 2012.
This work was supported by National Institutes of Health Grants NS047574 and MH064748, the Angelman Syndrome Foundation, and the Howard Hughes Medical Institute (M.D.E.). K.H.C. was supported by a fellowship from the Ruth K. Broad Foundation and a National Institutes of Health training grant to the Duke University Department of Neurobiology. We thank John Allen, Tom Helton, Ben Philpot, Joel Schwartz, and Koji Yashiro for helpful discussions and assistance; Richard Weinberg for assistance with electron microscopy; Marguerita Klein for generation of the pGolgi-CFP-YFP construct; Kewa Mou for assistance with embryonic mouse cultures; and John Allen, Juliet Hernandez, Angela Mabb, Tingting Wang, and Jason Yi for insightful discussions and critical comments on the manuscript.
M.D.E. is an employee and shareholder of Pfizer, Inc. The remaining authors declare no competing financial interests.
- Correspondence should be addressed to Dr. Michael D. Ehlers, Neuroscience Research Unit, Pfizer, Inc., 700 Main Street, Cambridge, MA 02139. michael.ehlers{at}pfizer.com
Online Impact
